ImmuneMed, Inc.   Report issue

For profit Phase 2
Founded: Chuncheon Korea, Republic of (2000)
Status: No NME R&D (2000)

Organization Overview

First Clinical Trial
2018
NCT03653208
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

ImmuneMed, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

hzvsf-v13 (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Pneumonia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 1